Injective (INJ) is currently priced at $6.33, reflecting a significant decline of 5.64% over the past 24 hours. The daily trading range has been narrow, with a high of $6.93 and a low of $6.32, indicating a consolidation phase amid bearish sentiment.

Volume stands at approximately $56 million, representing 8.86% of the market cap, suggesting moderate trading activity relative to its size. The hourly RSI is critically low at 23, indicating oversold conditions, while the 7-day RSI at 42 shows a weak momentum, implying further downside potential if selling pressure persists.

Technical indicators reveal a series of declining moving averages, with the 8 SMA at $6.70 down 5.58% and the 144 SMA significantly higher at $7.27, down 12.90%. This downward trend in moving averages suggests a bearish market structure, and price action is currently below these averages, reinforcing the negative outlook.

From a fundamental perspective, INJ has experienced notable declines over various time frames, including a 30-day price drop of approximately 24.52%. This prolonged downtrend indicates potential market weakness, raising concerns about recovery in the short term, especially with the recent performance.

Given the current technical and fundamental data, the immediate outlook for Injective (INJ) remains bearish. The combination of declining price momentum, critical oversold RSI levels, and a downward trend in moving averages suggests a cautious approach is warranted.

Rating: Sell. The ongoing downtrend and lack of bullish signals indicate that investors should consider liquidating positions or avoiding new investments until clearer signs of recovery emerge.